Neogenomics, Inc. NEO

Company Overview

NeoGenomics, Inc. is a specialized oncology diagnostics company operating within the clinical laboratory testing, precision medicine, and biopharmaceutical services industries. The company focuses on cancer-related genetic, molecular, and pathology testing that supports oncologists, hospitals, and pharmaceutical companies in diagnosing cancer, selecting targeted therapies, and monitoring disease progression. Its core offerings include anatomic pathology, molecular diagnostics, cytogenetics, next-generation sequencing (NGS), and liquid biopsy-based testing.

The company generates revenue primarily through clinical testing services ordered by healthcare providers and through advanced diagnostic and laboratory services provided to biopharmaceutical companies supporting drug development and clinical trials. NeoGenomics is positioned as a pure-play oncology diagnostics provider with an integrated testing platform and large-scale laboratory infrastructure. Founded in 2001, the company has evolved through organic expansion and acquisitions into one of the largest independent oncology-focused testing laboratories in the United States, completing its transition to a publicly traded company in 2012.